Literature DB >> 11418455

Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII.

P C Spiegel1, M Jacquemin, J M Saint-Remy, B L Stoddard, K P Pratt.   

Abstract

The development of an immune response to infused factor VIII is a complication affecting many patients with hemophilia A. Inhibitor antibodies bind to antigenic determinants on the factor VIII molecule and block its procoagulant activity. A patient-derived inhibitory immunoglobulin G4kappa antibody (BO2C11) produced by an immortalized memory B-lymphocyte cell line interferes with the binding of factor VIII to phospholipid surfaces and to von Willebrand factor. The structure of a Fab fragment derived from this antibody complexed with the factor VIII C2 domain was determined at 2.0 A resolution. The Fab interacts with solvent-exposed basic and hydrophobic side chains that form a membrane-association surface of factor VIII. This atomic resolution structure suggests a variety of amino acid substitutions in the C2 domain of factor VIII that might prevent the binding of anti-C2 inhibitor antibodies without significantly compromising the procoagulant functions of factor VIII.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418455     DOI: 10.1182/blood.v98.1.13

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  A structure-based benchmark for protein-protein binding affinity.

Authors:  Panagiotis L Kastritis; Iain H Moal; Howook Hwang; Zhiping Weng; Paul A Bates; Alexandre M J J Bonvin; Joël Janin
Journal:  Protein Sci       Date:  2011-02-16       Impact factor: 6.725

2.  The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells.

Authors:  Bagirath Gangadharan; Mathieu Ing; Sandrine Delignat; Ivan Peyron; Maud Teyssandier; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

3.  Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo.

Authors:  Kalpana Parvathaneni; David W Scott
Journal:  Blood Adv       Date:  2018-09-25

4.  Importance of a factor VIIIc-like glycoprotein expressed in capillary endothelial cells (eFactor VIIIc) in angiogenesis.

Authors:  Dipak K Banerjee; Caroline M Oliveira; José J Tavárez; Viswa N Katiyar; Subiman Saha; Juan A Martínez; Aditi Banerjee; Aurymar Sánchez; Krishna Baksi
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

Review 5.  Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 6.  Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies.

Authors:  Géraldine Lavigne-Lissalde; Chantal Rothschild; Claire Pouplard; Priscilla Lapalud; Yves Gruel; Jean-François Schved; Claude Granier
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

7.  Trp2313-His2315 of factor VIII C2 domain is involved in membrane binding: structure of a complex between the C2 domain and an inhibitor of membrane binding.

Authors:  Zhuo Liu; Lin Lin; Cai Yuan; Gerry A F Nicolaes; Liqing Chen; Edward J Meehan; Bruce Furie; Barbara Furie; Mingdong Huang
Journal:  J Biol Chem       Date:  2010-01-20       Impact factor: 5.157

Review 8.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

9.  Automated detection of conformational epitopes using phage display Peptide sequences.

Authors:  Surendra S Negi; Werner Braun
Journal:  Bioinform Biol Insights       Date:  2009-07-01

Review 10.  Progress in the understanding of the protein C anticoagulant pathway.

Authors:  Björn Dahlbäck
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.